nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adopting orphaned drugs: developing multidrug regimens using generic drugs
|
Turner, Timothy J. |
|
2011 |
|
3-4 |
p. 117-121 5 p. |
artikel |
2 |
Aging: approaches towards its control
|
Kapoor, Vijay Kumar |
|
2010 |
|
3-4 |
p. 43-44 2 p. |
artikel |
3 |
Aging control with resveratrol
|
Pallàs, Mercè |
|
2010 |
|
3-4 |
p. 51-56 6 p. |
artikel |
4 |
Anti-ageing potential of carnosine: approaches toward successful ageing
|
Kyriazis, Marios |
|
2010 |
|
3-4 |
p. 45-49 5 p. |
artikel |
5 |
Cheminformatic/bioinformatic analysis of large corporate databases: Application to drug repurposing
|
Loging, William |
|
2011 |
|
3-4 |
p. 109-116 8 p. |
artikel |
6 |
Contents
|
|
|
2010 |
|
3-4 |
p. i- 1 p. |
artikel |
7 |
Contents
|
|
|
2011 |
|
3-4 |
p. i- 1 p. |
artikel |
8 |
Drug repurposing
|
Lipinski, Christopher A. |
|
2011 |
|
3-4 |
p. 57-59 3 p. |
artikel |
9 |
Drug repurposing from an academic perspective
|
Oprea, Tudor I. |
|
2011 |
|
3-4 |
p. 61-69 9 p. |
artikel |
10 |
Drug repurposing through nonhypothesis driven phenotypic screening
|
Reaume, Andrew G. |
|
2011 |
|
3-4 |
p. 85-88 4 p. |
artikel |
11 |
Drugs and supplements that may slow aging of the epigenome
|
Cooney, Craig A. |
|
2010 |
|
3-4 |
p. 57-64 8 p. |
artikel |
12 |
Fibroblast aging: intrinsic and extrinsic factors
|
Varani, James |
|
2010 |
|
3-4 |
p. 65-70 6 p. |
artikel |
13 |
Formulation technology to repurpose drugs for inhalation delivery
|
Cipolla, David C. |
|
2011 |
|
3-4 |
p. 123-130 8 p. |
artikel |
14 |
Intellectual property and other legal aspects of drug repurposing
|
Witkowski, Timothy X. |
|
2011 |
|
3-4 |
p. 139-143 5 p. |
artikel |
15 |
Literature analysis for systematic drug repurposing: a case study from Biovista
|
Lekka, Eftychia |
|
2011 |
|
3-4 |
p. 103-108 6 p. |
artikel |
16 |
Orphan/rare drug discovery through drug repositioning
|
Muthyala, Ramaiah |
|
2011 |
|
3-4 |
p. 71-76 6 p. |
artikel |
17 |
Repositioned drugs: integrating intellectual property and regulatory strategies
|
Smith, Richard B. |
|
2011 |
|
3-4 |
p. 131-137 7 p. |
artikel |
18 |
Repositioning drugs to enhance a product's lifecycle
|
Phelps, Ken |
|
2011 |
|
3-4 |
p. 97-101 5 p. |
artikel |
19 |
The CTSA Pharmaceutical Assets Portal – a public–private partnership model for drug repositioning
|
Marusina, Kate |
|
2011 |
|
3-4 |
p. 77-83 7 p. |
artikel |
20 |
theraTRACE®: a mechanism unbiased in vivo platform for phenotypic screening and drug repositioning
|
Saporito, Michael S. |
|
2011 |
|
3-4 |
p. 89-95 7 p. |
artikel |